Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000012247
- Lead Sponsor
- Chubu Clinical Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Not provided
(1) Past history of severe hypersensitivity to drug (2) Severe infectious disease that requires systemic treatment (3) Second primary malignancy except in situ carcinoma or prior malignancy treated within 5 years (4) Serious illness (5) Congestive heart failure, unstable angina or myocardial infarction (6) Much amount of pleural effusion, ascites or cardiac effusion (7) Peripheral nerve disorder (8) Presence of symptomatic or progressing CNS metastasis (9) Psychological illness (10) Pregnant or lactating woman. Women of child bearing potential not using a contraceptive method. Sexually active fertile men not using effective birth control. (11) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease free survival
- Secondary Outcome Measures
Name Time Method